Related Experiment Video
Updated: Jun 14, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Glioma proteomics: status and perspectives
Simone P Niclou1, Fred Fack, Uros Rajcevic
1Norlux Neuro-Oncology Laboratory, Department of Oncology, Centre de Recherche Public de la Santé (CRP-Santé), Luxembourg, Luxembourg. simone.niclou@crp-sante.lu
Abstract:
High grade gliomas are the most common brain tumors in adults and their malignant nature makes them the fourth biggest cause of cancer death. Major efforts in neuro-oncology research are needed to reach similar progress in treatment efficacy as that achieved for other cancers in recent years. In addition to the urgent need to identify novel effective drug targets against malignant gliomas, the search for glioma biomarkers and grade specific protein signatures will provide a much needed contribution to diagnosis, prognosis, treatment decision and assessment of treatment response. Over the past years glioma proteomics has been attempted at different levels, including proteome analysis of patient biopsies and bodily fluids, of glioma cell lines and animal models. Here we provide an extensive review of the outcome of these studies in terms of protein identifications (protein numbers and regulated proteins), with an emphasis on the methods used and the limitations of the studies with regard to biomarker discovery. This is followed by a perspective on novel technologies and on the potential future contribution of proteomics in a broad sense to understanding glioma biology.
Insights
High grade gliomas are a major cause of cancer death. Proteomics research is crucial for identifying new drug targets and biomarkers to improve diagnosis and treatment for these aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Proteomics
- Cancer Research
Background:
- High grade gliomas are the most common adult brain tumors and the fourth leading cause of cancer mortality.
- Significant advancements in treating other cancers highlight the need for improved neuro-oncology research and treatment efficacy for gliomas.
- Identifying novel drug targets and specific protein signatures is essential for better diagnosis, prognosis, and treatment strategies for gliomas.
Purpose of the Study:
- To provide an extensive review of glioma proteomics studies.
- To analyze protein identifications, including protein numbers and regulated proteins from various glioma models.
- To emphasize the methods, limitations, and potential of proteomics in biomarker discovery for high grade gliomas.
Main Methods:
- Review of published glioma proteomics studies.
- Analysis of proteome data from patient biopsies, bodily fluids, cell lines, and animal models.
- Evaluation of protein identification data and methodologies employed.
Main Results:
- Summarizes protein identification outcomes from diverse glioma research levels.
- Highlights the methods utilized in past and current glioma proteomics investigations.
- Discusses the limitations encountered in proteomic studies concerning biomarker discovery.
Conclusions:
- Proteomics offers significant potential for understanding glioma biology and improving patient outcomes.
- Further research and novel technologies are needed to fully leverage proteomics for glioma biomarker discovery and therapeutic development.
- The review underscores the importance of proteomics in advancing neuro-oncology and addressing the challenges posed by high grade gliomas.
